Last reviewed · How we verify
cyclosporine micro-emulsion
Cyclosporine micro-emulsion is an immunosuppressant that inhibits calcineurin, blocking T-cell activation and proliferation.
Cyclosporine micro-emulsion is an immunosuppressant that inhibits calcineurin, blocking T-cell activation and proliferation. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Severe active rheumatoid arthritis, Severe psoriasis.
At a glance
| Generic name | cyclosporine micro-emulsion |
|---|---|
| Sponsor | Novartis |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Cyclosporine binds to cyclophilin and the resulting complex inhibits calcineurin phosphatase, which prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the transcription of IL-2 and other cytokines essential for T-cell activation, thereby suppressing cell-mediated immunity. The micro-emulsion formulation improves bioavailability and reduces food-dependent variability compared to conventional cyclosporine.
Approved indications
- Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)
- Severe active rheumatoid arthritis
- Severe psoriasis
- Nephrotic syndrome
- Uveitis
- Atopic dermatitis
Common side effects
- Nephrotoxicity
- Hypertension
- Tremor
- Gingival hyperplasia
- Hirsutism
- Headache
- Hyperkalemia
- Infection
Key clinical trials
- SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus (PHASE4)
- Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients (PHASE4)
- A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients (PHASE4)
- Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion (PHASE4)
- Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclosporine micro-emulsion CI brief — competitive landscape report
- cyclosporine micro-emulsion updates RSS · CI watch RSS
- Novartis portfolio CI